With pan-RAF drug from Takeda, Day One unveils its first pediatric brain cancer data. And the market loves it

Day One Biopharmaceuticals has gathered the first cut of Phase II data on its quest to reposition a Takeda drug as a treatment for pediatric …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With pan-RAF drug from Take­da, Day One un­veils its first pe­di­atric brain can­cer da­ta. And the mar­ket loves it